louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06500312: Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach（Radiogenomics-Lung）
Official title: Assessment the Association of Imaging and Tumor Microenvironment in Lung Cancer With Radiogenomics
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital Xi'an Jiaotong University
First posted: 2024-07-15
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients were treated for lung cancer

Brief summary: This is the prospective, observational cohort study (Radiogenomics-Lung), which aims to explore the relationship between the imaging information of lung cancer patients, tumor microenvironment and the prognosis of lung cancer patients.


Eligibility criteria: Inclusion Criteria:

1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2024 to July 2027;
2. Aged \> 18 years old;
3. At least one chest CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion Criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than lung cancer;
4. Unclear pathological diagnosis。

Primary outcomes:
measure: Correlation analysis of sequencing results and body composition
timeFrame: 0.5 year
measure: Correlation analysis of sequencing results and tumor radiomic features
timeFrame: 0.5 year
Secondary outcomes:
measure: Constructing tumor microenvironment prediction model
timeFrame: 2 years
measure: Constructing a multi-dimensional prognostic prediction model
timeFrame: 3 years
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT06504212: Validity and Reliability of a New Mobile Application
Official title: Reliability and Validity Of A Mobile Applicatıon in the Evaluation of Elbow Joint Position Sense
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Proprioception
Keywords: mobile application
validity
reliability
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2024-07-16
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy individuals

Brief summary: In this study, we aimed to study the validity and reliability of the Angle Meter, a Smartphone application for elbow joint position sense.

Detailed description: The validity and reliability of the elbow joint position sense with the mobile application will be evaluated with the angle meter. This application works on phones with the IOS operating system. The validity and reliability of the Angle Meter will be evaluated by comparing it with a small universal goniometer for measuring elbow range of motion. The elbows of healthy subjects will be photographed at 3 different angles in the open and kinetic chain position. The elbow photo of healthy individuals measured with the Angle meter will be evaluated simultaneously but independently with the Angle meter by 2 different evaluators. The measurements will be repeated after 3 days. It will be noted that each picture is sufficient, i.e. there is no obvious perspective error.

Eligibility criteria: Inclusion Criteria:

* Being between the ages of 18-25
* Being healthy
* Agreeing to participate in the study

Exclusion Criteria:

* Those who have had upper extremity surgery within the last year
* Those with neurological, orthopedic, rheumatic or cardiovascular problems affecting the neck, shoulder, elbow, hand and wrist
* Those with central and peripheral nervous system involvement Having pain anywhere in the body

Primary outcomes:
measure: universal goniometer
timeFrame: [Time Frame: 3 days]
measure: mobile application
timeFrame: [Time Frame: 3 days]
Secondary outcomes:
Other outcomes:
Locations:
city: Malatya
country: Turkey
facility: Gulfem Ezgi
state: Inonu University
Study officials:
affiliation: Inonu University
name: dilan demirtas karaoba
role: STUDY_CHAIR
affiliation: Inonu University
name: havva adli
role: STUDY_CHAIR
affiliation: Inonu University
name: burcu talu
role: STUDY_CHAIR
References:
Clinical trial NCT04125212: Air Pollution and Cardio-metabolic Health
Official title: Effects of Air Pollution on Cardio-metabolic Outcomes Among Heathy Adults
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiovascular Outcomes
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2019-10-14
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: non-smoker young healthy adults

Brief summary: To investigate the effects of air pollution on surrogate cardio-metabolic outcomes in young healthy adults.

Detailed description: To investigate the effects of air pollution on surrogate cardio-metabolic outcomes in a panel study involving young healthy adults living in Beijing, China with extreme high ambient air pollution levels.

Eligibility criteria: Inclusion Criteria:

1. Living in Peking University Health Science Center neighborhood.
2. Non smoker and no diseases.

Exclusion Criteria:

1. Advanced microvascular complications and active cardiovascular disease.
2. Pregnancy or intent to get pregnant during the study period.

Primary outcomes:
measure: Blood pressure
timeFrame: Four months
Secondary outcomes:
measure: Systemic inflammatory
timeFrame: Four months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University ,School of Public Health
state: Beijing
Study officials:
References:
Clinical trial NCT02236312: Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
Official title: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Glabellar Frown Lines
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2014-09-10
Enrollment: 359
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.


Eligibility criteria: Inclusion Criteria:

* Moderate to Very Severe glabellar lines at maximum frown as assessed by the subject and the Investigator and at least Mild glabellar lines at rest

Exclusion Criteria:

* Any previous treatment with any botulinum toxin
* Rhytids of the glabellar region that cannot be smoothed out by manually spreading the skin apart
* Any previous insertion of any permanent or semi-permanent material, hyaluronic acid or collagen fillers to the glabellar region
* Any history of facial surgery above the lower orbital rim
* Any planned facial surgery or aesthetic procedure during the study period
* Ablative skin resurfacing or chemical peels above the lower orbital rim in the previous 12 months or during the study period

Primary outcomes:
measure: Reduction of glabellar frown line severity on Day 14 following treatment with botulinum toxin
timeFrame: 14 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Private practice
state: Alabama
city: Mobile
country: United States
facility: Private practice
state: Alabama
city: San Diego
country: United States
facility: Private practice
state: California
city: Englewood
country: United States
facility: Private practice
state: Colorado
city: Aventura
country: United States
facility: Private practice
state: Florida
city: Nashville
country: United States
facility: Private practice
state: Tennessee
city: San Antonio
country: United States
facility: Private practice
state: Texas
city: Salt Lake City
country: United States
facility: Private practice
state: Utah
Study officials:
References:
Clinical trial NCT02948712: Adolescent and Young Adult Survivor Transition
Official title: Adolescent and Young Adult Survivor Transition (AYAST)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Adolescent and Young Adult Cancer
Keywords: distress
survivorship
transition period
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2016-10-28
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to help adolescents and young adult cancer survivors address their psycho-social needs during the transitional period. The transitional period begins at completion of cancer treatment and continues throughout that first year. Patients often report this period can be difficult and distressing in many areas of life. This study will use a simple tool to measure, on a regular basis, the level of distress a young adult may be feeling. Based on this assessment additional mental health support and intervention can be recommended to help cancer survivors cope and enhance their feelings of well-being.

Detailed description: Study Objective:

To establish a successful distress based intervention program for adolescent and young adult survivors in the transition period.

Study Design and Methods:

The type of design for this study is a feasibility pilot study with repeated measure, within group quantitative design. There is no randomization for this study. The patient will be assessed; at baseline, upon completion of therapy, and at regular three month intervals for the first year, for a total of five assessments. After receiving a referral a member of the AYAST team will contact the patient and set up the initial visit.

Eligibility criteria: Inclusion Criteria:

* Completed cancer treatment within the past three months of all cancer types and stages
* Signed, written consent

Exclusion Criteria:

* Have not completed cancer treatment within the past three months

Primary outcomes:
measure: Decrease in distress score according to National Comprehensive Cancer Network (NCCN) Guidelines V 1.0.2016
timeFrame: Up to 15 months after initial visit
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
name: Amelia Baffa, RN, MSN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05616312: Patient Recall After Orthopedic Trauma
Official title: Validating a "Teach-back" Protocol to Improve Recall in Orthopedic Trauma Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Education After Trauma
Lead sponsor: University Hospitals Cleveland Medical Center
Sponsor class: OTHER
First posted: 2022-11-15
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate whether receiving education after trauma surgeries affects three things: 1) knowledge about injury and treatment ("recall"), 2) how well patients follow treatment recommendations, and 3) how satisfied patients are with their care. To do so, some participants in this study will receive education, and some will not.


Eligibility criteria: Inclusion Criteria:

* Isolated open or closed fracture of the pelvis and/or lower extremity treated surgically

Exclusion Criteria:

* Patient receiving orthopedic care or follow-up at another institution
* Non-English speaking
* Incarcerated (or likely impending incarceration)
* Currently enrolled in a study that does not permit co-enrollment
* Traumatic brain injury, dementia, or other cognitive impairment

Primary outcomes:
measure: Number of correct answers to the recall-assessing items on the follow-up questionnaire.
timeFrame: Up to 45 minutes
measure: Adherence rate to postoperative weightbearing instructions as measured by patient report.
timeFrame: Up to 180 days post op
measure: Adherence rate to DVT prophylaxis instructions as measured by patient report.
timeFrame: Up to 180 days post op
measure: Mean satisfaction as measured by follow-up questionnaire.
timeFrame: Up to 180 days post op
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center
state: Ohio
Study officials:
affiliation: University Hospitals Cleveland Medical Center
name: John Sontich, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02522312: A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
Official title: A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dry Eye Syndrome
Keywords: Dry Eye
Lead sponsor: Hazleton Eye Specialists
Sponsor class: OTHER
First posted: 2015-08-13
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary Care Clinic

Brief summary: A retrospective analysis of Restasis® benefits in dry eye contact lens patients.

Detailed description: Charts of contact lens wearers with diagnosed dry eye who are being treated with Restasis will be evaluated to determine success in treatment by retrospectively looking at various outcome measures including but not limited to schirmer, staining and osmolarity levels

Eligibility criteria: Inclusion Criteria:

* Male or Female, \> or = 18 years of age
* Subject was previously diagnosed (prior to Baseline Visit) with mild to severe dry eye disease (ITF level 1, 2 or 3) which required continuous medical therapy with Restasis® for a minimum duration of 6 months post-Baseline (Visit 1); or Subject was newly diagnosed (at Baseline Visit) with mild to severe dry eye disease (ITF level 1, 2 or 3) which required continuous medical therapy with Restasis® for a minimum duration of 6 months post-Baseline (Visit 1);
* Subject was prescribed Restasis® therapy at Baseline Visit (Visit 1) and commenced dosing immediately after Baseline Visit (Visit 1)
* Baseline Visit occured between 01 July 2012 and 01 January 2014;
* Subject had corneal staining and at least one dry eye sign (i.e., Schirmer's Test score \<10 mm, decreased tear lake, TBUT \<10 seconds, conjunctival staining, tear osmolarity \>310 mOsmol/L
* Subject had charted tolerability and efficacy data reflecting at least one follow-up visit following Restasis® treatment initiation; and
* Subject wore contact lens(es) concurrently while receiving Restasis® treatment for a minimum duration of 6 months post-Baseline (Visit 1)

Exclusion Criteria:

-

Primary outcomes:
measure: Improvement of Schirmer's Test score
timeFrame: 6 months
measure: Increased contact lens wear time
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hazleton
country: United States
facility: Hazleton Eye Specialists
state: Pennsylvania
Study officials:
affiliation: Owner
name: Thomas P Kislan, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05515146: Lymphovascular Abnormalities Under Tattoos
Official title: Lymphovascular Abnormalities Under Tattoos : Preliminary Reports of One Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tattoo
Keywords: lymphatic vessels
indocyanin green
near infra red fluorescence lymphatic imaging
tattoo
Lead sponsor: Haute Ecole Bruxelles-Brabant
Sponsor class: OTHER
First posted: 2022-08-25
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: nineteen subjects (nine women and ten men; mean age = 28.6, range 23-39 years) with tattoos at the level, either of the lower limb (n = 11), or of the upper limb (n = 9) Except in 4 cases, tattoos were older than 2 years (mean = 52.5 months).

Brief summary: The number of tattooed people is increasing and some complications secondary to tattoos suggest that the lymphatic vascular system might be implicated in their pathogenesis. Abnormalities have been described at the level of the lymph nodes draining the tattooed areas but nothing was reported about the lymphatic vessels under tattoos. This is the aim of the present work.

Detailed description: 19 subjects with 20 tattooed skin surfaces were enrolled after written informed consent and the lymphvascular drainage under the tattooed surface was studied using one near infrared camera device after one intradermal injection of Indocyanine Green.

Eligibility criteria: Inclusion Criteria:

* presence of one tattoo at the level of one limb
* written informed consent

Exclusion Criteria:

1. History of iodine allergy or anaphylactic reactions to insect bites or medication;
2. Hyperthyroidism;
3. Severe cardiac or pulmonary disease;
4. Significant renal failure (creatinine \> 400 μmol/l);
5. Pregnancy;
6. any known disease of the skin (such as psoriasis);
7. any disease known to affect the cutaneous tissues (such as diabetes);
8. any previous operation and/or trauma at the level of tattooed limb;
9. familial history of lower limb edemas:
10. skin infection after the tattoo

Primary outcomes:
measure: normal or abnormal lympho-vascular drainage
timeFrame: imagings were performed directly after the injection (duration 3 minutes)
measure: normal or abnormal lympho-vascular drainage
timeFrame: imagings were performed directly after the stretching and massages (duration 3 minutes)
measure: normal or abnormal lympho-vascular drainage
timeFrame: imagings were performed after a period of normal activities (duration 30 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Paliseul
country: Belgium
facility: Pierre Bourgeois
Study officials:
References:
Clinical trial NCT04115046: The EUS ShearWave Elastography Liver Fibrosis Study
Official title: Pilot Study Evaluating Endoscopic Ultrasound With ShearWave Elastography for Diagnosis and Staging of Liver Fibrosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Fibroses
Lead sponsor: Olympus Corporation of the Americas
Sponsor class: INDUSTRY
Collaborators: name: Geisinger Clinic
First posted: 2019-10-03
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All consenting, eligible patients reporting for an ultrasound and/or liver biopsy for evaluation of fibrosis.

Brief summary: The study objective is to demonstrate the clinical performance of ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS) when compared to FibroScan for evaluation of liver fibrosis.

Detailed description: This study has been designed as prospective, single center, single arm, consecutive, blinded, pilot study conducted in a post-market setting using commercially available devices to evaluate the effectiveness of Endoscopic Ultrasound with ShearWave Elastography to estimate hepatic fibrosis in patients with chronic liver disease. It is anticipated that the data from this study will support the need for additional clinical trials. All consenting, eligible patients reporting for an ultrasound and/or liver biopsy for evaluation of fibrosis meeting the inclusion criteria will be consecutively enrolled into the study and assigned a unique study identification number. A total of 52 subjects will be enrolled and treated at a single study site in the US. Enrollment is expected to be completed within 6 months. Each subject will undergo both procedures (FibroScan and EUS with SW Elastography), End of study will be reached after pathology results have been obtained (within a week of the initial procedure).

Eligibility criteria: Inclusion Criteria:

1. ≥ 18 years of age
2. Willing and able to provide informed consent
3. Undergoing diagnostic EUS procedure with liver biopsy
4. Baseline CBC, CMP, INR within 3 months

Exclusion Criteria:

1. Contraindication to EUS-guided liver biopsy
2. Baseline platelet count \<50,000
3. Baseline INR \>1.5
4. Patient is a prisoner

Primary outcomes:
measure: Analyze the correlation between SWE of liver and FibroScan of liver with histologic fibrosis stage using Spearman Correlation Coefficient.
timeFrame: 6 months
measure: Analyze the correlation between SWE of liver and FibroScan of liver with histologic fibrosis stage using Spearman Correlation Coefficient.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Danville
country: United States
facility: Geisinger Medical Center
state: Pennsylvania
Study officials:
affiliation: Geisinger Clinic
name: David Diehl, MD
role: PRINCIPAL_INVESTIGATOR
References: